General
Preferred name
BEMPEDOIC ACID
Synonyms
ETC 1002 ()
ETC-1002 ()
ESP-55016 ()
ETC1002 ()
Bempedoic acid|ESP-55016 ()
Bempedoic acid, ESP-55016 ()
Nexletol ()
P&D ID
PD050470
CAS
738606-46-7
Tags
available
drug
Approved by
EMA
FDA
First approval
2020
Drug Status
investigational
approved
Drug indication
Cardiovascular disease
Familial hypercholesterolemia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Bempedoic acid is a novel investigational drug being developed for the treatment of dyslipidemia and related cardiovascular disease
DESCRIPTION Bempedoic acid (ETC-1002) is an orally delivered non-statin drug for treating dyslipidemia and related cardiovascular disease, which offers an additional pharmaceutical strategy for statin-refractory or statin-intolerant patients . Its novel mechanism of action makes it the first-in-class ATP citrate lyase (ACLY; P53396) inhibitor to reach the clinic . Bempedoic acid is in fact a prodrug, as it must be converted to its active metabolite bempedoic acid-CoA by endogenous liver acyl-CoA synthetase. Bempedoic acid-CoA is the bona fide ACLY inhibitor. ACLY is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA, which in turn is required for de novo lipogenesis and cholesterogenesis, and its inhibition directly reduces cholesterol synthesis in the liver . (GtoPdb)
Compound Sets
19
AdooQ Bioactive Compound Library
A15815
Cayman Chemical Bioactives
26409
ChEMBL Approved Drugs
CHEMBL3545313
ChEMBL Drugs
CHEMBL3545313
Drug Repurposing Hub
DrugBank
DB11936
DrugBank Approved Drugs
DB11936
DrugCentral
5382
DrugCentral Approved Drugs
5382
DrugMAP
DM1CI9R
DrugMAP Approved Drugs
DM1CI9R
Guide to Pharmacology
8321
Mcule NIBR MoA Box Subset
MCULE-4476618510
MedChem Express Bioactive Compound Library
HY-12357
NCATS Inxight Approved Drugs
1EJ6Z6Q368
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
etc-1002
TargetMol Bioactive Compound Library
T3625
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
344.26
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
14
Ring Count
0
Aromatic Ring Count
0
cLogP
4.47
TPSA
94.83
Fraction CSP3
0.89
Chiral centers
0.0
Largest ring
0.0
QED
0.4
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Neuroscience
Epigenetics
Metabolic Enzyme/Protease
PI3K/Akt/mTOR
Target
ACL
ACLY
AMPK
ATP citrate lyase
AMPK,ATP-citrate lyase,LDL
Member status
virtual
MOA
ATP Citrate Lyase inhibitor
AMPK inhibitor
Source data